- Home
- SKBL vs IFRX Comparison
SKBL vs IFRX Comparison
Compare SKBL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- IFRX
- Stock Information
- Founded
- SKBL 2012
- IFRX 2007
- Country
- SKBL Hong Kong
- IFRX Germany
- Employees
- SKBL N/A
- IFRX N/A
- Industry
- SKBL
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SKBL
- IFRX Health Care
- Exchange
- SKBL NYSE
- IFRX Nasdaq
- Market Cap
- SKBL 389.6M
- IFRX 65.8M
- IPO Year
- SKBL 2025
- IFRX 2017
- Fundamental
- Price
- SKBL $12.28
- IFRX $1.58
- Analyst Decision
- SKBL
- IFRX Strong Buy
- Analyst Count
- SKBL 0
- IFRX 4
- Target Price
- SKBL N/A
- IFRX $8.50
- AVG Volume (30 Days)
- SKBL 742.6K
- IFRX 270.8K
- Earning Date
- SKBL 01-01-0001
- IFRX 05-07-2025
- Dividend Yield
- SKBL N/A
- IFRX N/A
- EPS Growth
- SKBL N/A
- IFRX N/A
- EPS
- SKBL 0.03
- IFRX N/A
- Revenue
- SKBL $49,638,709.00
- IFRX $140,242.00
- Revenue This Year
- SKBL N/A
- IFRX $106.72
- Revenue Next Year
- SKBL N/A
- IFRX $66.89
- P/E Ratio
- SKBL $385.51
- IFRX N/A
- Revenue Growth
- SKBL 9.58
- IFRX 30.90
- 52 Week Low
- SKBL $6.93
- IFRX $0.82
- 52 Week High
- SKBL $13.50
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- IFRX 58.67
- Support Level
- SKBL N/A
- IFRX $1.42
- Resistance Level
- SKBL N/A
- IFRX $1.68
- Average True Range (ATR)
- SKBL 0.00
- IFRX 0.17
- MACD
- SKBL 0.00
- IFRX 0.04
- Stochastic Oscillator
- SKBL 0.00
- IFRX 64.37
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.